Identification of Stevens-Johnson syndrome and toxic epidermal necrolysis in electronic health record databases

被引:44
作者
Davis, Robert L. [1 ,2 ]
Gallagher, Mia A. [2 ]
Asgari, Maryam M. [3 ]
Eide, Melody J. [4 ]
Margolis, David J. [5 ]
Macy, Eric [6 ]
Burmester, James K. [7 ]
Selvam, Nandini [8 ]
Boscarino, Joseph A. [9 ]
Cromwell, Lee F. [2 ]
Feigelson, Heather S. [10 ]
Kuntz, Jennifer L. [11 ]
Pawloski, Pamala A. [12 ]
Penfold, Robert B. [13 ]
Raebel, Marsha A. [10 ]
Sridhar, Gayathri [8 ]
Wu, Ann [14 ]
La Grenade, Lois A. [15 ]
Pacanowski, Michael A. [15 ]
Pinheiro, Simone P. [15 ]
机构
[1] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA
[2] Kaiser Permanente Georgia, Atlanta, GA USA
[3] Kaiser Permanente Northern Calif, Oakland, CA USA
[4] Henry Ford Hosp, Detroit, MI 48202 USA
[5] Univ Penn, Philadelphia, PA 19104 USA
[6] Kaiser Permanente So Calif, Pasadena, CA 91101 USA
[7] Marshfield Clin Res Fdn, Marshfield, WI USA
[8] Healthcore, Wilmington, DE USA
[9] Geisinger Hlth Syst, Danville, PA USA
[10] Kaiser Permanente Colorado, Denver, CO USA
[11] Kaiser Permanente Northwest, Portland, OR USA
[12] HealthPartners Inst Educ & Res, Minneapolis, MN USA
[13] Grp Hlth Res Inst, Seattle, WA USA
[14] Harvard Pilgrim Hlth Care, Boston, MA USA
[15] US FDA, Silver Spring, MD USA
关键词
Stevens-Johnson syndrome; toxic epidermal necrolysis; pharmacoepidemiology; ADVERSE DRUG-REACTIONS; HLA-B-ASTERISK-1502; ALLELE; ERYTHEMA MULTIFORME; THAI POPULATION; CLAIMS DATA; CARBAMAZEPINE; ASSOCIATION; HLA-A-ASTERISK-3101; RISK;
D O I
10.1002/pds.3778
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
BackgroundStevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) carry a high mortality risk. While identifying clinical and genetic risk factors for these conditions has been hindered by their rarity, large electronic health databases hold promise for identifying large numbers of cases for study, especially with the introduction in 2008 of ICD-9 codes more specific for these conditions. ObjectiveThe objective of this study is to estimate the validity of ICD-9 codes for ascertaining SJS/TEN in 12 collaborating research units in the USA, covering almost 60 million lives. MethodsFrom the electronic databases at each site, we ascertained potential cases of SJS/TEN using ICD-9 codes. At five sites, a subset of medical records was abstracted and standardized criteria applied by board-certified dermatologists to adjudicate diagnoses. Multivariate logistic regression was used to identify factors independently associated with validated SJS/TEN cases. ResultsA total of 56591 potential cases of SJS/TEN were identified. A subset of 276 charts was selected for adjudication and 39 (of the 276) were confirmed as SJS/TEN. Patients with the ICD-9 codes introduced after 2008 were more likely to be confirmed as cases (OR 3.32; 95%CI 0.82, 13.47) than those identified in earlier years. Likelihood of case status increased with length of hospitalization. Applying the probability of case status to the 56591 potential cases, we estimated 475-875 to be valid SJS/TEN cases. ConclusionNewer ICD-9 codes, along with length of hospitalization, identified patients with a high likelihood of SJS/TEN. This is important for identification of subjects for future pharmacogenomics studies. Copyright (c) 2015 John Wiley & Sons, Ltd.
引用
收藏
页码:684 / 692
页数:9
相关论文
共 50 条
[41]   Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update [J].
Coias, Jennifer L. ;
Abbas, Laila F. ;
Cardones, Adela R. .
CURRENT DERMATOLOGY REPORTS, 2019, 8 (04) :219-233
[42]   Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis [J].
Fagot, JP ;
Mockenhaupt, M ;
Bouwes-Bavinck, JN ;
Naldi, L ;
Viboud, C ;
Roujeau, JC .
AIDS, 2001, 15 (14) :1843-1848
[43]   Wound Management in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis [J].
Jaller, Jose A. ;
McLellan, Beth N. ;
Balagula, Yevgeniy .
CURRENT DERMATOLOGY REPORTS, 2020, 9 (01) :58-72
[44]   Managing the ADR of Stevens-Johnson syndrome/toxic epidermal necrolysis [J].
Lian, Bertrand Sheng-Yang ;
Lee, Haur Yueh .
EXPERT OPINION ON DRUG SAFETY, 2022, 21 (08) :1039-1046
[45]   Wound Management in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis [J].
Jose A. Jaller ;
Beth N. McLellan ;
Yevgeniy Balagula .
Current Dermatology Reports, 2020, 9 :58-72
[46]   Otologic complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis [J].
Hotaling, Jeffrey M. ;
Hotaling, Andrew J. .
INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2014, 78 (08) :1408-1409
[47]   Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide [J].
Vivar, Karina L. ;
Mancl, Kimberly ;
Seminario-Vidal, Lucia .
CLINICAL CASE REPORTS, 2018, 6 (02) :258-261
[48]   Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients [J].
Garg, Vivek Kumar ;
Buttar, Harpal Singh ;
Bhat, Sajad Ahmad ;
Ainur, Nuftieva ;
Priya, Tannu ;
Kashyap, Dharambir ;
Tuli, Hardeep Singh .
RECENT ADVANCES IN INFLAMMATION & ALLERGY DRUG DISCOVERY, 2023, 17 (02) :110-120
[49]   Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Guide for Nurses [J].
Hanson, Leah M. ;
Bettencourt, Amanda P. .
AACN ADVANCED CRITICAL CARE, 2020, 31 (03) :281-295
[50]   Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis [J].
Abe, Riichiro .
JOURNAL OF DERMATOLOGY, 2015, 42 (01) :42-48